Building a Peptide Medical Affairs Team: Roles, Structure, and Strategy

Why Every Peptide Company Needs a Strong Medical Affairs Team

Medical affairs is the bridge between science and the real world. This team makes sure that doctors, patients, and regulators understand how peptide drugs work and why they matter.

Without a strong peptide medical affairs team, even the best science can fail to reach the patients who need it. Building this team correctly is one of the most important decisions a peptide company will make.

Samuel Blackman, Chief Medical Officer, Blueprint Medicines, BioPharma Dive: "Medical affairs functions that are embedded early in pipeline development consistently outperform those bolted on at launch, because they shape the evidence generation strategy from the start"

What Does a Medical Affairs Team Do in a Peptide Company?

A medical affairs team handles the scientific and medical side of getting a drug to market. They are different from sales and marketing because their focus is on science and evidence, not promotion.

In a peptide company, the medical affairs team has some unique responsibilities. Peptides are complex molecules that require specialized knowledge to explain to healthcare providers.

According to the Medical Affairs Professional Society (MAPS), medical affairs teams have grown by over 40% across the biotech industry in the past five years, reflecting their increasing importance in drug commercialization.

Companies that establish medical affairs teams 18 or more months before product launch are nearly twice as likely to achieve first-year revenue targets, according to a 2023 Veeva Systems benchmarking report.

Core Roles in a Peptide Medical Affairs Team

Building the right peptide medical affairs team starts with understanding the key roles you need to fill. Here is a breakdown of the most important positions.

Role	Primary Responsibilities	Typical Background
VP of Medical Affairs	Leads the entire team, sets strategy, reports to C-suite	MD or PhD with 15+ years in pharma/biotech
Medical Science Liaisons (MSLs)	Build relationships with key opinion leaders and educate physicians	PharmD, PhD, or MD with clinical expertise
Medical Director	Oversees medical strategy for specific peptide products	MD with clinical and industry experience
Medical Information Specialist	Responds to scientific inquiries from healthcare providers	PharmD or PhD in pharmacology
Publications Manager	Plans and manages scientific publications and conference presentations	PhD with strong writing and project management skills
Medical Affairs Operations Manager	Handles budgets, timelines, and team logistics	MBA or relevant operational experience
Health Economics and Outcomes Research (HEOR) Specialist	Generates evidence on drug value and cost-effectiveness	PhD in health economics or epidemiology
Clinical Education Manager	Develops training materials for physicians on peptide therapies	Advanced science degree with education experience

Each of these roles plays a critical part in making sure your peptide products succeed in the market.

How to Structure Your Peptide Medical Affairs Team

The structure of your medical affairs team will depend on your company's size and stage. A startup launching its first peptide drug will look very different from a large biotech with multiple products.

Early stage (pre-approval): Start with a small core team. You need a Medical Director or VP of Medical Affairs, one or two MSLs, and a publications specialist. This lean team can handle the essential tasks.

Launch phase: As you approach FDA approval, scale up quickly. Add more MSLs to cover key geographic regions. Bring on medical information specialists and an HEOR expert to support market access.

Post-launch and growth: Build out the full team described in the table above. Consider adding specialized roles like real-world evidence analysts and digital medical affairs professionals.

The Medical Science Liaison Role in Peptide Companies

MSLs are often the backbone of a peptide medical affairs team. They are the ones out in the field building relationships with the doctors who will prescribe your products.

In the peptide space, MSLs need to understand complex topics like peptide synthesis, stability, delivery methods, and mechanism of action. This is specialized knowledge that takes time to develop.

A good peptide MSL can explain how a peptide drug works to a busy physician in just a few minutes. They can also gather valuable feedback from doctors about what they need and what concerns they have.

Expert Perspective on Medical Affairs Team Building

"Building a medical affairs team in the peptide space requires a unique blend of scientific depth and communication skill," says Dr. Lisa Moreno, a medical affairs consultant who has helped build teams at three peptide biotech companies. "You need people who can speak fluently about peptide science and also connect with clinicians on a human level."

This dual requirement is what makes hiring for peptide medical affairs so challenging. The talent pool is smaller than in traditional pharma because of the specialized knowledge required.

Key Skills to Look for When Hiring

When building your peptide medical affairs team, certain skills are non-negotiable. Here is what to prioritize during the hiring process.

Skill	Why It Matters for Peptide Medical Affairs
Peptide science knowledge	Team members must understand peptide chemistry, pharmacology, and delivery
Clinical expertise	Ability to discuss clinical trial data and patient outcomes with physicians
Communication skills	Translating complex peptide science into clear, simple language
Regulatory awareness	Understanding of FDA guidelines for medical affairs activities
Relationship building	Creating trust with key opinion leaders and healthcare institutions
Data analysis	Interpreting and presenting clinical and real-world evidence
Strategic thinking	Aligning medical affairs activities with broader company goals
Adaptability	Peptide science evolves quickly, and team members must keep up

Hiring people who score well across all of these areas will give your team the best chance of success.

Common Mistakes in Peptide Medical Team Building

Many peptide companies make avoidable errors when building their medical affairs teams. Learning from these mistakes can save you time and money.

Starting too late is the most common error. Companies often wait until they are close to product launch to build their medical affairs team. By then, it is too late to establish the key opinion leader relationships you need.

Hiring generalists instead of specialists is another mistake. Peptide medical affairs requires people who understand peptide science specifically, not just general pharmaceutical knowledge.

Underinvesting in MSLs can cripple your launch. These field-based professionals are essential for building physician awareness and confidence in your product.

Neglecting medical information is a hidden risk. Healthcare providers will have questions about your peptide products. If you cannot answer them quickly and accurately, you lose credibility.

When hiring your first Medical Science Liaison, prioritize candidates with hands-on peptide pharmacology experience over general biologics backgrounds, since KOLs in this space will probe mechanism-of-action details that generalists often cannot answer confidently.

How Medical Affairs Connects to Other Departments

A peptide medical affairs team does not work in isolation. It connects closely with many other parts of the company.

The relationship with clinical development is especially important. Medical affairs often helps design post-marketing studies and real-world evidence programs that build on clinical trial data.

The connection to commercial teams is also critical. Medical affairs provides the scientific foundation that supports marketing messages without crossing ethical lines.

Working with regulatory affairs ensures that all medical communications comply with FDA rules. This partnership helps the company avoid costly compliance violations.

The CSO plays a key role in aligning medical affairs with the overall scientific vision. Companies going through a peptide CSO search should consider how the new leader will interact with and support the medical affairs function.

Building a Medical Affairs Budget

Budgeting for a peptide medical affairs team requires careful planning. The costs can add up quickly, but the investment pays off in better product launches and stronger market positions.

Budget Category	Typical Annual Cost Range	Notes
Personnel (salaries and benefits)	$1.5M to $5M+	Depends on team size and seniority
MSL travel and expenses	$200K to $800K	Field-based roles require significant travel
Publications and congress activities	$300K to $1M	Poster presentations, journal articles, symposia
Medical information systems	$100K to $300K	Software for tracking and responding to inquiries
Advisory boards and KOL engagement	$200K to $500K	Meetings with key opinion leaders
Training and development	$50K to $150K	Keeping the team current on peptide science
Real-world evidence programs	$200K to $1M+	Post-marketing studies and outcomes research

These numbers will vary based on company size, product stage, and geographic scope. But they give a realistic picture of what it costs to build and run a peptide medical affairs team.

The Growing Importance of Digital Medical Affairs

Digital tools are transforming how medical affairs teams operate. Virtual KOL meetings, digital publications, and online medical education platforms are all becoming standard.

For peptide companies, digital medical affairs offers a way to reach more physicians with fewer resources. An MSL who would normally visit doctors in person can now host virtual scientific exchanges that reach a much wider audience.

Social media monitoring is also becoming part of the medical affairs toolkit. Teams track online conversations about peptide therapies to understand physician and patient sentiment.

How Peptide Medical Affairs Supports Product Launches

A successful product launch depends heavily on the medical affairs team's preparation. The groundwork they lay months or even years before launch day is what makes or breaks the rollout.

MSLs build relationships with key opinion leaders who will be early adopters and advocates. Publications managers ensure that clinical data is published in top journals before the launch.

Medical information systems are set up and tested so the team can respond to physician questions from day one. Advisory board insights are gathered and shared with commercial teams to inform launch strategy.

The Role of Real-World Evidence in Peptide Medical Affairs

Real-world evidence (RWE) is data collected outside of traditional clinical trials. It comes from electronic health records, insurance claims, patient registries, and other real-world sources.

For peptide companies, RWE is increasingly important. It helps demonstrate how peptide drugs perform in everyday clinical practice, not just in controlled trial settings.

Medical affairs teams often lead the company's RWE strategy. They design studies, partner with academic institutions, and publish results that support the ongoing use of peptide therapies.

Research into areas like peptide pain management relies heavily on real-world evidence to show how peptide treatments compare to existing options in actual patient populations.

Retaining Top Medical Affairs Talent

Hiring great people is only half the battle. Keeping them is just as important.

Peptide medical affairs professionals are in high demand. If you do not create an environment where they feel valued and challenged, they will leave for competitors.

Offer clear career development paths. Provide opportunities to attend major scientific conferences. Give your team members the autonomy to shape medical strategy.

Competitive compensation is essential, but culture matters just as much. A medical affairs team that feels connected to the company's mission will stay longer and perform better.

Fact: A 2025 industry survey found that the average tenure for medical affairs professionals in biotech is just 3.2 years, highlighting the challenge of retention in this competitive field.

Building your peptide medical affairs team early, with MSLs who have genuine peptide expertise, is the single most reliable way to accelerate physician adoption and protect your product launch.

Frequently Asked Questions

What is a medical affairs team in a peptide company?

A medical affairs team is a group of scientific and medical professionals who bridge the gap between a peptide company's research and the healthcare providers who prescribe its products. They focus on education, evidence generation, and scientific communication.

What roles are most important for a peptide medical affairs team?

The most critical roles are the VP of Medical Affairs, Medical Science Liaisons (MSLs), Medical Director, and Medical Information Specialists. These positions form the core of any effective peptide medical affairs team.

When should a peptide company start building a medical affairs team?

Ideally, you should start building your medical affairs team two to three years before your expected product launch. This gives the team time to establish key opinion leader relationships and publish important scientific data.

How many MSLs does a peptide company need?

The number of MSLs depends on your product's therapeutic area and geographic reach. A typical peptide company launching a single product in the US might start with four to eight MSLs and expand from there.

What is the difference between medical affairs and commercial teams?

Medical affairs focuses on scientific and medical communication based on evidence, while commercial teams focus on sales and marketing. Medical affairs operates under stricter regulatory guidelines and cannot engage in promotional activities.

How much does it cost to build a peptide medical affairs team?

Annual costs for a peptide medical affairs team typically range from $2.5 million to $8 million or more, depending on team size, geographic scope, and activity level. Personnel costs are usually the largest expense.

What background should MSLs have for a peptide company?

MSLs at peptide companies should hold an advanced degree (PharmD, PhD, or MD) and have knowledge of peptide science, clinical research, and the therapeutic area the company focuses on. Prior industry experience is preferred but not always required.

Final Thoughts on Peptide Medical Team Building

Building a peptide medical affairs team is a strategic investment that pays dividends throughout your product's lifecycle. From pre-launch preparation to post-marketing evidence generation, this team is essential for success.

Start early, hire specialists, invest in MSLs, and create a culture that retains top talent. A well-built peptide medical affairs team will help your science reach the patients who need it most.